<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophrenia (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Schizophrenia (Heidelb)</journal-id><journal-id journal-id-type="pmc-domain-id">4224</journal-id><journal-id journal-id-type="pmc-domain">schz</journal-id><journal-title-group><journal-title>Schizophrenia</journal-title></journal-title-group><issn pub-type="epub">2754-6993</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10185672</article-id><article-id pub-id-type="pmcid-ver">PMC10185672.1</article-id><article-id pub-id-type="pmcaid">10185672</article-id><article-id pub-id-type="pmcaiid">10185672</article-id><article-id pub-id-type="pmid">37188714</article-id><article-id pub-id-type="doi">10.1038/s41537-023-00356-x</article-id><article-id pub-id-type="publisher-id">356</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Influencing factors of medication adherence in schizophrenic patients: a meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="J">Jing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lv</surname><given-names initials="X">Xue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kong</surname><given-names initials="L">Lingling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Qu</surname><given-names initials="H">Haiying</given-names></name><address><email>qhy8949@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1201-8465</contrib-id><name name-style="western"><surname>Yue</surname><given-names initials="W">Weihua</given-names></name><address><email>dryue@bjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.440653.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9588 091X</institution-id><institution>Department of Psychology, Medical Humanities Research Center, </institution><institution>Binzhou Medical University, </institution></institution-wrap>Yantai, 264003 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.459847.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0615</institution-id><institution>Peking University Sixth Hospital, Peking University Institute of Mental Health, </institution></institution-wrap>Beijing, 100191 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.459847.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0615</institution-id><institution>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), </institution></institution-wrap>Beijing, 100191 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.11135.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2256 9319</institution-id><institution>NHC Key Laboratory of Mental Health (Peking University), </institution></institution-wrap>Beijing, 100191 China </aff><aff id="Aff5"><label>5</label>The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan 453100 China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.11135.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2256 9319</institution-id><institution>PKU-IDG/McGovern Institute for Brain Research, </institution><institution>Peking University, </institution></institution-wrap>Beijing, 100871 China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.510934.a</institution-id><institution-id institution-id-type="ISNI">0000 0005 0398 4153</institution-id><institution>Chinese Institute for Brain Research, </institution></institution-wrap>Beijing, 102206 China </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>9</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">425253</issue-id><elocation-id>31</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>13</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>17</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-24 13:25:16.723"><day>24</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41537_2023_Article_356.pdf"/><abstract id="Abs1"><p id="Par1">Medication adherence of schizophrenic patients is a growing public health problem. We conducted a meta-analysis on the influencing factors of medication compliance in schizophrenic patients. We searched PubMed, Embase, Cochrane Library, and Web Of Science for relevant articles published up to December 22, 2022. Combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess influencing factors. Egger&#8217;s test, funnel plot, the trim and fill method, and meta-regression analysis were used to assess publication bias. A total of 20 articles were included in the analysis. Twenty influencing factors were divided into seven categories: drug factors (OR&#8201;=&#8201;1.96, 95% CI: 1.48&#8211;2.59), problem behavior (OR&#8201;=&#8201;1.77, 95% CI: 1.43&#8211;2.19), income and quality of life (OR&#8201;=&#8201;1.23, 95% CI: 1.08&#8211;1.39), personal characteristics (OR&#8201;=&#8201;1.21, 95% CI: 1.14&#8211;1.30), disease factors (OR&#8201;=&#8201;1.14, 95% CI: 1.98&#8211;1.21), support level (OR&#8201;=&#8201;0.54, 95% CI: 0.42&#8211;0.70), and positive attitude and behavior (OR&#8201;=&#8201;0.52, 95% CI: 0.45&#8211;0.62). This meta-analysis found that drug factors, disease factors, problem behavior, low income and quality of life, and factors related to personal characteristics appear to be risk factors for medication adherence in people with schizophrenia. And support level, positive attitude and behavior appear to be protective factors.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Schizophrenia</kwd><kwd>Psychiatric disorders</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Schizophrenia is a common severe mental disease with a lifelong prevalence rate of 1%, which is mainly manifested in the disorder of mental and psychological processes such as thinking, perception, self-experience, cognition, will, emotion and behavior, and has the characteristics of high disability rate, repeated illness and prolonged course<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. The pathogenesis of schizophrenia is complex and not clear at present. Genetic susceptibility, abnormal neurotransmitter function and external factors may all contribute to the development of schizophrenia<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par3">The current treatment of schizophrenia is based on the administration of antipsychotic medication. Medication can control the condition of schizophrenic patients, which has been effective in the alleviation of positive symptoms, prevention of relapse, and extension of life expectancy<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>. The extent to which patients follow the prescribed time intervals and dosage requirements is defined as medication adherence<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. A Low degree is considered as poor medication adherence. Medication non-adherence behaviors include not taking medication on time, not taking more or less medication according to the dose, stopping the medication and reducing medication by themselves.</p><p id="Par4">Good medication adherence is the key to the effectiveness of drug treatment. Poor medication adherence will cause many problems in schizophrenic patients<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. First, low medication compliance will lead to low efficacy and high relapse. Some articles pointed out that the symptoms of schizophrenia developed the fastest in the five years before the onset of schizophrenia, dosing on time and at the right dose is an important factor in the effectiveness of treatment, irregular medication is the key risk factor for relapse<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. In a retrospective analysis of 419 psychiatric inpatients readmitted to hospital, Barnett et al. found that patients&#8217; medication non-adherence significantly increased the risk of readmission compared to other factors, with an OR of 3.33<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>; data from Verdoux et al. show that the most common cause of relapse and readmission in adult studies is the discontinuation of prescription drugs. Patients who do not insist on medication are six times more likely to be admitted to the hospital again than those who insist on medication<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. Furthermore, many studies have shown that poor medication adherence is associated with problematic behaviors such as violence, self-harm, and suicide. Buchanan et al. found that there was a significant positive correlation between low drug compliance and harmful violence through 18-month follow-ups of 1435 schizophrenic patients<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>; D&#237;az-Fern&#225;ndez et al. pointed out that the lack of treatment compliance of schizophrenic patients is a risk factor for the increase of suicidal behavior<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>; the results of a multicenter clinical trial in China also show that the aggression risk of schizophrenia patients is related to non-adherence to medication<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par5">Through a review of medication non-adherence behavior in schizophrenia patients, Lacro et al. noted that current medication non-adherence in schizophrenia patients is as high as 40&#8211;50%<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Fenton et al. reported a median non-adherence rate of 55% for oral antipsychotics<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and other data in the literature on medication non-adherence in schizophrenia patients ranging from 20 to 89%<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>. In recent years, many studies have been reported on the phenomenon of poor medication adherence in patients with schizophrenia, while the factors influencing medication adherence have also become a subject of scholarly interest. Available clinical observations and cohort studies suggest that patients&#8217; age, gender, marital status, insight, other physical illnesses, economic conditions, etc. all have an impact on medication adherence<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par6">However, the current research lacks uniform predictors and has no clinical implications for interventions for medication adherence in patients with schizophrenia. Understanding the factors that influence medication adherence has practical implications for the identification of patients with low adherence and may assist in the development of clinical interventions for medication adherence. The aim of this study was to analyze the influencing factors of medication adherence of schizophrenic patients, to provide information for the formulation of intervention strategies for medication adherence, and to help patients recover better and reduce recurrence.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Search strategy and inclusion criteria</title><p id="Par7">We conducted a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The initial study protocol was preregistered at PROSPERO (CRD42023388661). We searched PubMed, Embase, Cochrane Library, and Web of Science for relevant literature up to 22 December 2022.</p><p id="Par8">The search consisted of the following terms as Medical Subject Headings (MSH) and different databases have corresponding modifications. The following search strategy was used: (schizo*) AND (adherence OR compliance OR non-adherence OR non-compliance) AND (relative OR risk*) AND (cohort OR &#8220;cohort study&#8221;).</p><p id="Par9">Two researchers independently assessed the title and abstract that met the potential qualifications of the above search strategy to exclude the following articles: (i) use of long-acting injectable (LAI) antipsychotics; (ii) no relevant diagnosis of schizophrenia; (iii) review articles, comments, case reports, editorials, animal studies, and meta-analysis; (iv) data unextractable or incomplete; (v) language not English. The full text was then further assessed to determine whether the article met the inclusion criteria. The final articles included met the following criteria: (i) patients diagnosed with schizophrenia who are receiving at least one antipsychotic drug, and excluded patients with major medical conditions (such as liver or kidney dysfunction in relationship to cardiovascular disease organic brain disorders), with a history of substance use disorders; (ii) the study was designed as a cohort study or a cross-sectional study; (iii) the hazard ratios (HR), relative risks (RR), and odds ratios (OR) were reported.</p></sec><sec id="Sec4"><title>Data extraction and quality assessment</title><p id="Par10">All data were extracted independently by two investigators and the following data were collected for all articles: author, year of publication, country, sample size, sample age, diagnostic criteria, and influencing factors for medication adherence.</p><p id="Par11">In terms of quality assessment, we used the Agency for Healthcare Research and Quality Checklist<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> to assess the cross-sectional studies, and The Newcastle Ottawa Scale (NOS)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> was used to assess the cohort study. For each score, 1 indicates that the study meets this criterion and 0 indicates that the study does not meet this criterion. A total score of no less than 5 will be included in this meta-analysis.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par12">In this meta-analysis, Stata 14.0 was used for data analysis<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. We used the <italic toggle="yes">Q</italic>-test and <italic toggle="yes">I</italic>-squared (<italic toggle="yes">I</italic><sup>2</sup>) values to assess heterogeneity. <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1 and <italic toggle="yes">I</italic><sup>2</sup>&#8201;&gt;&#8201;75% was considered significant heterogeneity. <italic toggle="yes">I</italic>-squared (<italic toggle="yes">I</italic><sup>2</sup>) values close to 0% and <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.1 indicate that heterogeneity is small. Sensitivity analysis was carried out for the parts with large heterogeneity. Given the expected heterogeneity, we adopted the random effect model in advance. The odds ratio (OR) was used as the main index, and a 95% confidence interval (95% CI) was used to reflect the uncertainty of point estimation, with ORs&#8201;=&#8201;1 indicating that the factor was not associated with medication adherence, ORs&#8201;&lt;&#8201;1 considered as protective factors and ORs&#8201;&gt;&#8201;1 as risk factors.</p><p id="Par13">For publication bias, we used funnel plots for rough qualitative analysis combined with Egger&#8217;s test for quantitative analysis, significant Egger&#8217;s test result (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) indicated the presence of publication bias. For results showing publication bias, we used the trim and fill method to assess the impact of bias on final outcomes. In addition, to consider potential moderating effects, we used meta-regression to assess the country of study, the type of population (first patients or not), the type of study (cohort/cross-sectional study), and the quality of the literature.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Search results and character of studies</title><p id="Par14">A total of 564 articles were retrieved in the initial stage, and 477 articles were left after deleting duplicates. The titles and abstracts were initially screened to remove articles that were not relevant to the content of the review articles. After reading the full text of 100 articles, a total of twenty articles were included in this meta-analysis (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Flow chart of the search for relevant references.</title><p>The figure represents the amount of literature excluded/included after each step.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e513" position="float" orientation="portrait" xlink:href="41537_2023_356_Fig1_HTML.jpg"/></fig></p><p id="Par15">Of the 20 studies eventually included, five were cross-sectional studies, and the remaining fifteen were cohort studies. The age range was 14&#8211;65 years and the diagnostic criteria for schizophrenia were DSM or ICD. The relevant information extracted for the included literature is presented in Table <xref rid="Tab1" ref-type="table">1</xref>. A total of 20 studies had two quality assessment scores of 8, 9 scores of 7, 7 scores of 6, and 2 scores of 5. All met the inclusion criteria, the specific quality assessment scores see Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM1" ref-type="media">2</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of studies included in the meta-analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Author</th><th colspan="1" rowspan="1">Year</th><th colspan="1" rowspan="1">Study Design</th><th colspan="1" rowspan="1">Sample size <italic toggle="yes">N</italic></th><th colspan="1" rowspan="1">Sample age M (SD)</th><th colspan="1" rowspan="1">Period</th><th colspan="1" rowspan="1">Diagnostic criteria</th><th colspan="1" rowspan="1">Influencing factors</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Olfson, M.</td><td colspan="1" rowspan="1">2000</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">34.8&#8201;&#177;&#8201;9.7</td><td colspan="1" rowspan="1">18 months</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Substance abuse, past non-compliant behavior, family support</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR24">24</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Acosta, F. J.</td><td colspan="1" rowspan="1">2009</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">42.4&#8201;&#177;&#8201;11.7</td><td colspan="1" rowspan="1">3 months</td><td colspan="1" rowspan="1">ICD-10</td><td colspan="1" rowspan="1">Insight, disease severity</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR47">47</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Gearing, R. E.</td><td colspan="1" rowspan="1">2009</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">15.35&#8201;&#177;&#8201;2.08</td><td colspan="1" rowspan="1">at least 2 years</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Number of drugs</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR48">48</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Hill, M.</td><td colspan="1" rowspan="1">2010</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">29.1&#8201;&#177;&#8201;12.0</td><td colspan="1" rowspan="1">4 years</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Alcohol and drug abuse, duration of illness</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR49">49</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Lambert, M.</td><td colspan="1" rowspan="1">2010</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">605</td><td colspan="1" rowspan="1">15&#8211;29</td><td colspan="1" rowspan="1">18 months</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Number of medications, severity of illness, insight</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR50">50</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Conti, V.</td><td colspan="1" rowspan="1">2012</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">4975</td><td colspan="1" rowspan="1">46.4&#8201;&#177;&#8201;15.3</td><td colspan="1" rowspan="1">1 years</td><td colspan="1" rowspan="1">ICD-10</td><td colspan="1" rowspan="1">Employment, city life, marriage, hospitalization</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR51">51</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Hui, C. L. M.</td><td colspan="1" rowspan="1">2016</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">313</td><td colspan="1" rowspan="1">38.2&#8201;&#177;&#8201;8.4</td><td colspan="1" rowspan="1">6 months</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Severity of illness, hospitalization at onset, social support, attitudes to treatment</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR52">52</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Anderson, J. P.</td><td colspan="1" rowspan="1">2017</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">308</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">1 years</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Psychological interventions, age, family support, alcohol and drug abuse, gender, education level, attitudes to treatment, social support</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR53">53</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Conus, P.</td><td colspan="1" rowspan="1">2017</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">584</td><td colspan="1" rowspan="1">22.1&#8201;&#177;&#8201;3.4</td><td colspan="1" rowspan="1">18 months</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Severity of illness, level of education, social support</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR54">54</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Daneault, J. G.</td><td colspan="1" rowspan="1">2019</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">421</td><td colspan="1" rowspan="1">14&#8211;35</td><td colspan="1" rowspan="1">2 years</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Alcohol or drug abuse, severity of illness</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR55">55</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Desai, R.</td><td colspan="1" rowspan="1">2019</td><td colspan="1" rowspan="1">Cross-sectional study</td><td colspan="1" rowspan="1">496</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">ICD-9</td><td colspan="1" rowspan="1">Gender, family support, level of education</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Rezansoff, S. N.</td><td colspan="1" rowspan="1">2019</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">1996</td><td colspan="1" rowspan="1">35.4&#8201;&#177;&#8201;9.4</td><td colspan="1" rowspan="1">17 months</td><td colspan="1" rowspan="1">ICD-9</td><td colspan="1" rowspan="1">Attitude to treatment, amount of medication</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR57">57</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Tan, C. Z.</td><td colspan="1" rowspan="1">2019</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">445</td><td colspan="1" rowspan="1">26.3&#8201;&#177;&#8201;6.6</td><td colspan="1" rowspan="1">1 years</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Gender, family support, self-knowledge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR58">58</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Wang, D.</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1">Cross-sectional study</td><td colspan="1" rowspan="1">1189</td><td colspan="1" rowspan="1">34.22&#8201;&#177;&#8201;12.29</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Age, income, hospitalized at onset, severity of illness</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR59">59</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Guitter, M.</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">136</td><td colspan="1" rowspan="1">29.5&#8201;&#177;&#8201;9.9</td><td colspan="1" rowspan="1">1 years</td><td colspan="1" rowspan="1">ICD-10</td><td colspan="1" rowspan="1">Single, family support, hospitalized, other physical illness, active treatment</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR60">60</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Rubio, J. M.</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">512</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">8 years</td><td colspan="1" rowspan="1">ICD-10</td><td colspan="1" rowspan="1">Female, first hospitalization, other physical illness, age &lt;25, substance abuse</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR61">61</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Stockbridge, E.</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Cross-sectional study</td><td colspan="1" rowspan="1">1778</td><td colspan="1" rowspan="1">18&#8211;64</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">ICD-10</td><td colspan="1" rowspan="1">Age &gt;50, education, level of mental health, substance abuse, other physical illness</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR62">62</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Verdoux, H.</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1">Cross-sectional study</td><td colspan="1" rowspan="1">326</td><td colspan="1" rowspan="1">32.9&#8201;&#177;&#8201;0.4</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">DSM-V</td><td colspan="1" rowspan="1">Number of drugs, efficacy, side effects, quality of life, psychological interventions, level of education, self-knowledge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR63">63</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Cho, S. J.</td><td colspan="1" rowspan="1">2022</td><td colspan="1" rowspan="1">Cohort study</td><td colspan="1" rowspan="1">326917</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">6 months</td><td colspan="1" rowspan="1">ICD-10</td><td colspan="1" rowspan="1">Sex, hospitalized at onset, income</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR64">64</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Kirchner, S. K.</td><td colspan="1" rowspan="1">2022</td><td colspan="1" rowspan="1">Cross-sectional study</td><td colspan="1" rowspan="1">1062</td><td colspan="1" rowspan="1">42.82&#8201;&#177;&#8201;12.98</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">DSM-IV</td><td colspan="1" rowspan="1">Attitude to treatment, medication dose, quality of life, alcohol or drug abuse</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR65">65</xref></sup></td></tr></tbody></table></table-wrap></p><p id="Par16">Twenty articles reported twenty influencing factors of medication adherence, such as the number of medications taken, medication effectiveness, medication side effects, duration of illness, the severity of disease, insight, education level, gender, age, and social support level. There was high heterogeneity between factors (<italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;95.6%&#8201;&gt;&#8201;75%, <italic toggle="yes">Q</italic>-test: <italic toggle="yes">P</italic>&#8201;=&#8201;0.01&#8201;&lt;&#8201;0.1), and very significant. Therefore, we divided the different influencing factors into seven categories and discussed them respectively (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Risk of all factor analysis of included studies in this meta-analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Influencing factor</th><th colspan="1" rowspan="1">No. of studies</th><th colspan="1" rowspan="1">Heterogeneity</th><th colspan="1" rowspan="1">Pooled OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="2" rowspan="1">Pooled effect size test</th></tr><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">I</italic><sup>2</sup> (%)</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">Z</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Drug factors</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">85.0</td><td colspan="1" rowspan="1">1.96</td><td colspan="1" rowspan="1">1.48&#8211;2.59</td><td colspan="1" rowspan="1">2.59</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Disease factors</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">75.4</td><td colspan="1" rowspan="1">1.14</td><td colspan="1" rowspan="1">1.98&#8211;1.21</td><td colspan="1" rowspan="1">4.55</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Personal factors</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">86.4</td><td colspan="1" rowspan="1">1.21</td><td colspan="1" rowspan="1">1.14&#8211;1.30</td><td colspan="1" rowspan="1">5.75</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Support level</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">62.1</td><td colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1">0.42&#8211;0.70</td><td colspan="1" rowspan="1">4.60</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Positive attitudes and behavior</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">88.5</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">0.45&#8211;0.62</td><td colspan="1" rowspan="1">7.94</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Problem behaviors</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">65.9</td><td colspan="1" rowspan="1">1.77</td><td colspan="1" rowspan="1">1.43&#8211;2.19</td><td colspan="1" rowspan="1">5.26</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Income and quality of life</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">73.5</td><td colspan="1" rowspan="1">1.23</td><td colspan="1" rowspan="1">1.08&#8211;1.39</td><td colspan="1" rowspan="1">3.23</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Overall (risk)</td><td rowspan="2" colspan="1">73</td><td colspan="1" rowspan="1">89.4</td><td colspan="1" rowspan="1">1.13</td><td colspan="1" rowspan="1">1.25&#8211;1.37</td><td colspan="1" rowspan="1">11.76</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">(Protective)</td><td colspan="1" rowspan="1">83.2</td><td colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1">0.47&#8211;0.61</td><td colspan="1" rowspan="1">9.44</td><td colspan="1" rowspan="1">0.001</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Drug factors</title><p id="Par17">Data from a total of eight studies containing the number of drugs taken, the therapeutic effect of drugs, and the side effects of drugs are classified as drug factors. Meta-analysis using randomized effects showed that drug factors were the risk factors of medication adherence in schizophrenic patients (OR: 1.96, 95% CI: 1.48&#8211;2.59, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;85%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>). Sensitivity analyses showed little effect of removing either literature on the analysis, indicating reliable arithmetic for random effects, indicating that the operation results of random effects are reliable Egger&#8217;s test showed that there was no publication bias (<italic toggle="yes">P</italic>&#8201;=&#8201;0.54&#8201;&gt;&#8201;0.05).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Forest plots for medication factors, personal characteristics, level of support, positive attitudes and behaviors, problem behaviors, income and quality of life.</title><p><bold>A</bold> Forest plot of effect sizes and 95% CI for medication factors (random effects model). <bold>B</bold> Forest plot of effect sizes and 95% CI for personal characteristics factors (random effects model). <bold>C</bold> Forest plot of effect sizes and 95% CI for support levels (random effects model. <bold>D</bold> Forest plot of effect sizes and 95% CI for positive attitudes and behaviors (random effects model). <bold>E</bold> Problem behaviors. <bold>F</bold> Effect sizes for income and standard of living and forest plots with 95% CI (random effects model). Diamonds represent individual studies and combined effect sizes, and these lines represent 95% confidence intervals for each main study. OR odds ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1488" position="float" orientation="portrait" xlink:href="41537_2023_356_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Disease factors</title><p id="Par18">A total of fourteen data items were included in the analysis of disease factors, including elements such as duration of disease, severity of disease, level of insight, and other physical illnesses in combination. The results of the meta-analysis based on random effects showed that the related factors of the disease would cause the non-compliance with medication to a certain extent (OR: 1.41, 95% CI: 1.08&#8211;1.21, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;75. 4, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (Fig. <xref rid="Fig3" ref-type="fig">3A</xref>). Subgroup analysis of various factors showed that other physical diseases (OR: 1.31, 95% CI: 1.15&#8211;1.50) and insight (OR: 1.30, 95% CI: 1.12&#8211;1.50) had a great influence on medication compliance (Fig. <xref rid="Fig3" ref-type="fig">3B</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Forest plots and subgroup analysis of disease factors.</title><p><bold>A</bold> Forest plot of effect size and 95% CI of disease factors (random effects model). <bold>B</bold> Forest plot for subgroup analysis of disease factors (disease severity, other physical illness, self-knowledge). The diamonds represent individual studies and pooled effect sizes, and the lines represent 95% confidence intervals for each main study. OR odds ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1523" position="float" orientation="portrait" xlink:href="41537_2023_356_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Personal characteristics</title><p id="Par19">A total of thirteen studies with data on age, gender, education level, and other factors in personal characteristics were included. Meta-analysis showed that there was a significant correlation between individual factors and medication compliance (OR: 1.21, 95% CI: 1.14&#8211;1.30, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;86.4%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>).</p></sec><sec id="Sec11"><title>Support level</title><p id="Par20">The level of support mainly includes social support and family support and involves ten sets of data. Meta-analysis showed that support level was a protective factor for medication adherence in schizophrenic patients (OR: 0.54, 95% CI: 0.42&#8211;0.70, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;62.1%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), that is, the higher the level of support, the better the medication adherence (Fig. <xref rid="Fig2" ref-type="fig">2C</xref>).</p></sec><sec id="Sec12"><title>Positive attitudes and behavior</title><p id="Par21">Fourteen studies were included in the category of positive attitudes and behaviors. Positive treatment attitude refers to the degree of cooperation with physician treatment, and positive behaviors included immediate hospitalization and regular psychological intervention at the onset of the disease. The combined OR value was 0.52 (95% CI: 0.45&#8211;0.62, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;88.5%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), which indicated that positive treatment attitude and behavior were protective factors of medication adherence (Fig. <xref rid="Fig2" ref-type="fig">2D</xref>).</p></sec><sec id="Sec13"><title>Problem behavior</title><p id="Par22">Eight data sets on alcohol and substance abuse are included in the analysis of problem behavior. Results of a meta-analysis based on a random effects model showed that problem behavior was a risk factor for medication adherence (OR: 1.77, 95% CI: 1.43&#8211;2.19, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;65.9%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (Fig. <xref rid="Fig2" ref-type="fig">2E</xref>).</p></sec><sec id="Sec14"><title>Income and quality of life</title><p id="Par23">A randomized meta-analysis of six groups of data showed that low income and low quality of life were risk factors for medication compliance in schizophrenic patients (OR: 1.23, 95% CI: 1.08&#8211;1.39, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;73.5%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (Fig. <xref rid="Fig2" ref-type="fig">2F</xref>).</p></sec><sec id="Sec15"><title>Publication bias</title><p id="Par24">Funnel plots were conducted for the seven factor categories and the scatter distribution in the funnel plots was asymmetrical for all factors except positive attitudes and behaviors, suggesting that there may be publication bias. Then we further carried out Egger&#8217;s test on the factor categories and found that all the other five factors except drug factor (<italic toggle="yes">P</italic>&#8201;=&#8201;0.538) and positive attitude and behavior (<italic toggle="yes">P</italic>&#8201;=&#8201;0.204) had publication bias (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (Table <xref rid="Tab3" ref-type="table">3</xref>), which may be due to publication bias. Supplementing the virtual literature with publication bias for the five factors that had publication bias by a trim and fill method revealed very stable results for illness factors, personal traits, level of support and problem behavior, indicating that publication bias had little effect on the study results. In contrast, the results for income and quality of life were not stable, suggesting that publication bias had an impact on the results of the meta-analysis and that more studies need to be included in this factor to reduce publication bias. In addition, we did an overall Egger&#8217;s test for all factors and found that the test results were not significant (<italic toggle="yes">P</italic>&#8201;=&#8201;0.976&#8201;&gt;&#8201;0.05), suggesting that there was no publication bias (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Publication bias test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Influencing factors</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Drug factors</td><td colspan="1" rowspan="1">0.538</td></tr><tr><td colspan="1" rowspan="1">Disease factors</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Personal factors</td><td colspan="1" rowspan="1">0.044</td></tr><tr><td colspan="1" rowspan="1">Support level</td><td colspan="1" rowspan="1">0.016</td></tr><tr><td colspan="1" rowspan="1">Positive attitudes and behaviors</td><td colspan="1" rowspan="1">0.204</td></tr><tr><td colspan="1" rowspan="1">Problem behaviors</td><td colspan="1" rowspan="1">0.003</td></tr><tr><td colspan="1" rowspan="1">Income and quality of life</td><td colspan="1" rowspan="1">0.012</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">0.976</td></tr></tbody></table></table-wrap><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Overall funnel plot.</title><p>The dotted lines represent 95% confidence intervals, and the dots represent studies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1714" position="float" orientation="portrait" xlink:href="41537_2023_356_Fig4_HTML.jpg"/></fig></p><p id="Par25">In addition to the funnel plots and Egger&#8217;s test, we conducted a meta-regression analysis with the study country, population type (whether first-episode patients), study type and literature quality as variables to further explore the possible sources of heterogeneity. The results showed that population type (<italic toggle="yes">b</italic>&#8201;=&#8201;0.87, <italic toggle="yes">P</italic>&#8201;=&#8201;0.49), research type (<italic toggle="yes">b</italic>&#8201;=&#8201;0.89, <italic toggle="yes">P</italic>&#8201;=&#8201;0.50), and literature quality (<italic toggle="yes">b</italic>&#8201;=&#8201;1.08, <italic toggle="yes">P</italic>&#8201;=&#8201;0.49) were not significant sources of heterogeneity. Study countries (<italic toggle="yes">b</italic>&#8201;=&#8201;3.80, <italic toggle="yes">P</italic>&#8201;=&#8201;0.03) may be a source of heterogeneity. Therefore, we conducted a subgroup analysis of the study countries. A total of 12 countries were involved in this meta-analysis, and the results of the subgroup analysis showed that only two countries had low subgroup heterogeneity (<italic toggle="yes">I</italic><sup>2</sup>&#8201;&lt;&#8201;50%, <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.1), while the majority of countries still had high subgroup heterogeneity (Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>). This suggests that the study country moderates heterogeneity to some extent, but is not itself a significant source of heterogeneity.</p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p id="Par26">It has been noted that the indirect, direct and readmission costs associated with schizophrenia amount to tens of billions of dollars per year<sup><xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref></sup>, and more and more related costs are considered to be related to non-adherence to medication<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. As early as 1999, the National Center for Mental Health Research emphasized the importance of treatment compliance among patients with mental illness<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Although some studies have pointed out that long-acting injectable drugs are an effective way to improve patient adherence to medication<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, it has certain individual tolerance problems<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and the high price will bring great economic pressure on patients<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par27">Understanding the factors related to medication compliance can guide us to screen compliance assessment tools and develop practical interventions to better help patients recover to the maximum extent. To our knowledge, this is the first meta-analysis to explore the factors influencing medication adherence in the schizophrenia population.</p><p id="Par28">This study was based on a meta-analysis of five cross-sectional studies and fifteen cohort studies with an overall sample of 342,408 patients taking antipsychotic medication. The data of meta-analysis showed that a total of five categories of factors were potential risk factors for medication adherence, with a combined OR of 1.31 (95% CI: 1.25&#8211;1.37, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;89.4, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05): drug factors (multiple drug doses, poor drug efficacy, high medication side effect response), disease factors (long duration of disease, high severity of disease, combined with other physical diseases, weak insight), personal characteristics (age&#8201;&gt;&#8201;50, age&#8201;&lt;&#8201;25, female, with low education level), problem behavior (alcohol abuse, drug abuse), lower income, and lower quality of life. Two categories of factors were protective for medication adherence, with a combined OR of 0.54 (95% CI: 0.47&#8211;0.61, <italic toggle="yes">I</italic><sup>2</sup>&#8201;=&#8201;83.2, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05): higher levels of support (family support, social support), and positive treatment attitudes and behaviors.</p><p id="Par29">Among the results of the analysis of risk factors, medication factors had the greatest impact on medication adherence in patients with schizophrenia (OR&#8201;=&#8201;1.96). The results suggest that the therapeutic effect, dosage, and severity of side effects of drugs will lead to patients&#8217; non-compliance behavior. This is consistent with previous research results<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. Therefore, clinicians should combine these dimensions in the selection of patients&#8217; therapeutic drugs to ensure maximum adherence. At the same time, due to the lack of literature, this paper has not analyzed the types of drugs. This is also the limitation of this article. Some studies have shown that adherence to medication is higher with clozapine<sup><xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR42">42</xref></sup> and risperidone<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> compared to other antipsychotics, and that adherence is higher with atypical antipsychotics than with typical antipsychotics<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. This suggests that the choice of medication type affects patients&#8217; medication adherence, and future analyses could extend this section of the data to explore this further.</p><p id="Par30">In addition to drug factors, the results of our meta-analysis showed that disease-related factors such as problem behaviors of drug and alcohol abuse (OR&#8201;=&#8201;1.77), duration and severity of illness (OR&#8201;=&#8201;1.14) can also influence medication adherence to a large extent. This is consistent with the findings of several previous studies<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. Also, lower income and quality of life (OR&#8201;=&#8201;1.23), personal attributes including age, gender, and education (OR&#8201;=&#8201;1.21), were all significant in the results of this meta-analysis and were among the risk factors for patient medication adherence. This is different from the results of Lacro et al.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, which may be caused by different inclusion criteria and different data processing methods.</p><p id="Par31">In terms of protective factors for medication adherence, we found two significant results: support level (OR&#8201;=&#8201;0.54), positive attitude and behavior (OR&#8201;=&#8201;0.52). Regarding the level of support, both family members (such as a spouse, parents, etc.) and social support (medical policy support, friendly social environment, etc.) would increase medication adherence in patients with schizophrenia and also reduce patients&#8217; stigma to a certain extent, especially for patients recovering from the illness. Positive treatment attitude and behavior, including seeing a doctor in time when the disease occurs, insisting on psychological intervention and actively learning related knowledge, etc. These are helpful to the compliance of taking medicine, and at the same time, better guarantee the exertion of drug effect. This is consistent with a previous reanalysis of 38 control studies by Pitsche-l Walz et al., which showed that psychological education can improve the medication compliance of schizophrenia patients, and its one-year recurrence rate can be reduced by 20%<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par32">Generally speaking, medication adherence is the basic guarantee for schizophrenic patients to obtain the curative effect, which can better help patients recover and reduce recurrence, and then reduce the economic burden on family and society. The results of this meta-analysis may help identify low adherence to medication in patients with schizophrenia and inform the development of prevention protocols. Specifically, the results of the above five risk factors suggest that we have substance abuse behavior, low income, and low life satisfaction, age &lt;25 or age &gt;50, females with low education level are more likely to have drug non-adherence behavior, and we should focus on monitoring the population with the above characteristics. At the same time, combining the results of the two main protective factors we found that interventions targeting the problem of medication adherence can be aimed at improving patients&#8217; life satisfaction, level of support, developing positive attitudes and behaviors, and educating about medication adherence as entry points.</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec17"><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41537_2023_356_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>SUPPLEMENTAL MATERIAL</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41537-023-00356-x.</p></sec><ack><title>Acknowledgements</title><p>We would like to thank colleagues in our lab for their feedbacks and technical assistances.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>W.Y. and J.G. conceived and designed the study. J.G. and X.L. extracted the data and assessed the risk of bias. J.G. and Y.L. analyzed the data. W.Y. supervised the data analyses. J.G. and L.K. interpreted the data. J.G. drafted the paper, and X.L. and H.Q. contributed to revising the paper. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuevo</surname><given-names>R</given-names></name><etal/></person-group><article-title>The continuum of psychotic symptoms in the general population: a cross-national study</article-title><source>Schizophr. Bull.</source><year>2012</year><volume>38</volume><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbq099</pub-id><pub-id pub-id-type="pmid">20841326</pub-id><pub-id pub-id-type="pmcid">PMC3329982</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>PB</given-names></name></person-group><article-title>Schizophrenia</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>86</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01121-6</pub-id><pub-id pub-id-type="pmid">26777917</pub-id><pub-id pub-id-type="pmcid">PMC4940219</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wens</surname><given-names>J</given-names></name><name name-style="western"><surname>Vermeire</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Royen</surname><given-names>P</given-names></name><name name-style="western"><surname>Hearnshaw</surname><given-names>H</given-names></name></person-group><article-title>A systematic review of adherence with medications for diabetes: response to Cramer</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>2284</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.9.2284</pub-id><pub-id pub-id-type="pmid">15333510</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fountoulakis</surname><given-names>KN</given-names></name><etal/></person-group><article-title>The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia</article-title><source>CNS Spectr.</source><year>2020</year><volume>22</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1092852920001546</pub-id><pub-id pub-id-type="pmid">32594935</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taipale</surname><given-names>H</given-names></name><etal/></person-group><article-title>20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)</article-title><source>World Psychiatry</source><year>2020</year><volume>19</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1002/wps.20699</pub-id><pub-id pub-id-type="pmid">31922669</pub-id><pub-id pub-id-type="pmcid">PMC6953552</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kane</surname><given-names>JM</given-names></name></person-group><article-title>What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?</article-title><source>World Psychiatry</source><year>2018</year><volume>17</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1002/wps.20516</pub-id><pub-id pub-id-type="pmid">29856543</pub-id><pub-id pub-id-type="pmcid">PMC5980517</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar disorder: a real-world study using US claims data</article-title><source>Adv. Ther.</source><year>2018</year><volume>35</volume><fpage>1612</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1007/s12325-018-0785-y</pub-id><pub-id pub-id-type="pmid">30206822</pub-id><pub-id pub-id-type="pmcid">PMC6182631</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clifford</surname><given-names>L</given-names></name><name name-style="western"><surname>Crabb</surname><given-names>S</given-names></name><name name-style="western"><surname>Turnbull</surname><given-names>D</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>L</given-names></name><name name-style="western"><surname>Galletly</surname><given-names>C</given-names></name></person-group><article-title>A qualitative study of medication adherence amongst people with schizophrenia</article-title><source>Arch. Psychiatr. Nurs.</source><year>2020</year><volume>34</volume><fpage>194</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.apnu.2020.06.002</pub-id><pub-id pub-id-type="pmid">32828348</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsman</surname><given-names>J</given-names></name><name name-style="western"><surname>Taipale</surname><given-names>H</given-names></name><name name-style="western"><surname>Masterman</surname><given-names>T</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A</given-names></name></person-group><article-title>Adherence to psychotropic medication in completed suicide in Sweden 2006&#8211;2013: a forensic-toxicological matched case-control study</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2019</year><volume>75</volume><fpage>1421</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1007/s00228-019-02707-z</pub-id><pub-id pub-id-type="pmid">31218371</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Khoury</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Projecting the long-term economic impact of once-monthly paliperidone palmitate versus oral atypical antipsychotics in medicaid patients with schizophrenia</article-title><source>J. Manag. Care Spec. Pharm.</source><year>2020</year><volume>26</volume><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">32011960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2020.26.2.176</pub-id><pub-id pub-id-type="pmcid">PMC10390979</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joubert</surname><given-names>AF</given-names></name></person-group><article-title>Providing quality care to patients with schizophrenia</article-title><source>Psychiatr. Clin. N. Am.</source><year>2003</year><volume>26</volume><fpage>213</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/S0193-953X(02)00013-8</pub-id><pub-id pub-id-type="pmid">12683267</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Risk factors for readmission among a cohort of psychiatric inpatients in Lilongwe, Malawi</article-title><source>Int. J. Psychiatry Clin. Pract.</source><year>2020</year><volume>24</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1080/13651501.2019.1699116</pub-id><pub-id pub-id-type="pmid">31799886</pub-id><pub-id pub-id-type="pmcid">PMC7085440</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdoux</surname><given-names>H</given-names></name><etal/></person-group><article-title>Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects</article-title><source>Acta Psychiatr. Scand.</source><year>2000</year><volume>102</volume><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0447.2000.102003203.x</pub-id><pub-id pub-id-type="pmid">11008856</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdoux</surname><given-names>H</given-names></name><name name-style="western"><surname>Liraud</surname><given-names>F</given-names></name><name name-style="western"><surname>Assens</surname><given-names>F</given-names></name><name name-style="western"><surname>Abalan</surname><given-names>F</given-names></name><name name-style="western"><surname>van Os</surname><given-names>J</given-names></name></person-group><article-title>Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients</article-title><source>Schizophr. Res.</source><year>2002</year><volume>56</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(01)00225-0</pub-id><pub-id pub-id-type="pmid">12084429</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchanan</surname><given-names>A</given-names></name><name name-style="western"><surname>Sint</surname><given-names>K</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>R</given-names></name></person-group><article-title>Correlates of future violence in people being treated for schizophrenia</article-title><source>Am J Psychiatry</source><year>2019</year><volume>176</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2019.18080909</pub-id><pub-id pub-id-type="pmid">31014102</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az-Fern&#225;ndez</surname><given-names>S</given-names></name><name name-style="western"><surname>Fr&#237;as-Ortiz</surname><given-names>DF</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Miranda</surname><given-names>JJ</given-names></name></person-group><article-title>Suicide attempts in people with schizophrenia before and after participating in an intensive case managed community program: a 20-year follow-up</article-title><source>Psychiatry Res.</source><year>2020</year><volume>287</volume><fpage>112479</fpage><pub-id pub-id-type="doi">10.1016/j.psychres.2019.112479</pub-id><pub-id pub-id-type="pmid">31377009</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Optimizing and individualizing the pharmacological treatment of first-episode schizophrenic patients: study protocol for a multicenter clinical trial</article-title><source>Front. Psychiatry</source><year>2021</year><volume>12</volume><fpage>611070</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2021.611070</pub-id><pub-id pub-id-type="pmid">33716817</pub-id><pub-id pub-id-type="pmcid">PMC7947302</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacro</surname><given-names>JP</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>LB</given-names></name><name name-style="western"><surname>Dolder</surname><given-names>CR</given-names></name><name name-style="western"><surname>Leckband</surname><given-names>SG</given-names></name><name name-style="western"><surname>Jeste</surname><given-names>DV</given-names></name></person-group><article-title>Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature</article-title><source>J. Clin. Psychiatry</source><year>2002</year><volume>63</volume><fpage>892</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.4088/JCP.v63n1007</pub-id><pub-id pub-id-type="pmid">12416599</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenton</surname><given-names>WS</given-names></name><name name-style="western"><surname>Blyler</surname><given-names>CR</given-names></name><name name-style="western"><surname>Heinssen</surname><given-names>RK</given-names></name></person-group><article-title>Determinants of medication compliance in schizophrenia: empirical and clinical findings</article-title><source>Schizophr. Bull.</source><year>1997</year><volume>23</volume><fpage>637</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1093/schbul/23.4.637</pub-id><pub-id pub-id-type="pmid">9366000</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>I</given-names></name><name name-style="western"><surname>Khalily</surname><given-names>MT</given-names></name><name name-style="western"><surname>Hallahan</surname><given-names>B</given-names></name><name name-style="western"><surname>Shah</surname><given-names>I</given-names></name></person-group><article-title>Factors associated with psychotic relapse in patients with schizophrenia in a Pakistani cohort</article-title><source>Int. J. Ment. Health Nurs.</source><year>2017</year><volume>26</volume><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1111/inm.12260</pub-id><pub-id pub-id-type="pmid">27704675</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolder</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lacro</surname><given-names>JP</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>LB</given-names></name><name name-style="western"><surname>Jeste</surname><given-names>DV</given-names></name></person-group><article-title>Antipsychotic medication adherence: is there a difference between typical and atypical agents? [published correction appears in Am J Psychiatry 2002 Mar;159(3):514]</article-title><source>Am. J. Psychiatry</source><year>2002</year><volume>159</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.1.103</pub-id><pub-id pub-id-type="pmid">11772697</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caseiro</surname><given-names>O</given-names></name><etal/></person-group><article-title>Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study</article-title><source>J. Psychiatr. Res.</source><year>2021</year><volume>46</volume><fpage>1099</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2012.05.001</pub-id><pub-id pub-id-type="pmid">22721546</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priebe</surname><given-names>S</given-names></name><etal/></person-group><article-title>Factors influencing subjective quality of life in patients with schizophrenia and other mental disorders: a pooled analysis</article-title><source>Schizophr. Res.</source><year>2010</year><volume>121</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2009.12.020</pub-id><pub-id pub-id-type="pmid">20483566</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predicting medication noncompliance after hospital discharge among patients with schizophrenia</article-title><source>Psychiatr. Serv.</source><year>2000</year><volume>51</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.51.2.216</pub-id><pub-id pub-id-type="pmid">10655006</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karow</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia</article-title><source>J. Clin. Psychiatry</source><year>2007</year><volume>68</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.4088/JCP.v68n0110</pub-id><pub-id pub-id-type="pmid">17284133</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flottorp</surname><given-names>SA</given-names></name><etal/></person-group><article-title>A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice</article-title><source>Implement. Sci.</source><year>2013</year><volume>8</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1748-5908-8-35</pub-id><pub-id pub-id-type="pmid">23522377</pub-id><pub-id pub-id-type="pmcid">PMC3617095</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stang</surname><given-names>A</given-names></name></person-group><article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title><source>Eur. J. Epidemiol.</source><year>2010</year><volume>25</volume><fpage>603</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1007/s10654-010-9491-z</pub-id><pub-id pub-id-type="pmid">20652370</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poorolajal</surname><given-names>J</given-names></name><name name-style="western"><surname>Noornejad</surname><given-names>S</given-names></name></person-group><article-title>Metaplot: a new Stata module for assessing heterogeneity in a meta-analysis</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><fpage>e0253341</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0253341</pub-id><pub-id pub-id-type="pmid">34181682</pub-id><pub-id pub-id-type="pmcid">PMC8238175</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>BE</given-names></name></person-group><article-title>Comprehensive Textbook of Psychiatry. 7th Edition, 2 volumes. Edited by Bergamin J. Sadock and Virgina A. Sadock, Lippincott, William and Wilkins</article-title><source>Hum. Psychopharmacol. Clin. Exp.</source><year>2000</year><volume>3500</volume><fpage>389</fpage><lpage>389</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-1077(200007)15:5&amp;#x0003c;389::AID-HUP223&amp;#x0003e;3.0.CO;2-G</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennington</surname><given-names>M</given-names></name><name name-style="western"><surname>McCrone</surname><given-names>P</given-names></name></person-group><article-title>The cost of relapse in schizophrenia</article-title><source>Pharmacoeconomics.</source><year>2017</year><volume>35</volume><fpage>921</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1007/s40273-017-0515-3</pub-id><pub-id pub-id-type="pmid">28534254</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>EQ</given-names></name><etal/></person-group><article-title>The economic burden of schizophrenia in the United States in 2002</article-title><source>J. Clin. Psychiatry</source><year>2005</year><volume>66</volume><fpage>1122</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.4088/JCP.v66n0906</pub-id><pub-id pub-id-type="pmid">16187769</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasich</surname><given-names>LD</given-names></name><etal/></person-group><article-title>The National council on patient information and education</article-title><source>J.Am. Med. Assoc.</source><year>1997</year><volume>278</volume><fpage>1491</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03550180041026</pub-id><pub-id pub-id-type="pmid">9363963</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Mental Health: A Report of the Surgeon General (1999). U.S. National Library of Medicine.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldessarini</surname><given-names>RJ</given-names></name></person-group><article-title>Chemiotherapy in psychiatry</article-title><source>Pharmacol. Basis Treat. Major Ment. Illn.</source><year>2013</year><volume>18</volume><fpage>404</fpage><lpage>407</lpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawley</surname><given-names>C</given-names></name><etal/></person-group><article-title>Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety</article-title><source>Hum. Psychopharmacol.</source><year>2010</year><volume>25</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/hup.1085</pub-id><pub-id pub-id-type="pmid">20041474</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tempest</surname><given-names>M</given-names></name><name name-style="western"><surname>Sapin</surname><given-names>C</given-names></name><name name-style="western"><surname>Beillat</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>P</given-names></name><name name-style="western"><surname>Treur</surname><given-names>M</given-names></name></person-group><article-title>Cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UK</article-title><source>J. Ment. Health Policy Econ.</source><year>2015</year><volume>18</volume><fpage>185</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">26729007</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorillo</surname><given-names>A</given-names></name><etal/></person-group><article-title>The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review</article-title><source>Ann. Gen. Psychiatry</source><year>2020</year><volume>19</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s12991-020-00293-4</pub-id><pub-id pub-id-type="pmid">32774442</pub-id><pub-id pub-id-type="pmcid">PMC7409631</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sendt</surname><given-names>KV</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>DK</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>S</given-names></name></person-group><article-title>A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders</article-title><source>Psychiatry Res.</source><year>2015</year><volume>225</volume><fpage>14</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2014.11.002</pub-id><pub-id pub-id-type="pmid">25466227</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phan</surname><given-names>SV</given-names></name></person-group><article-title>Medication adherence in patients with schizophrenia</article-title><source>Int. J. Psychiatry Med.</source><year>2016</year><volume>51</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1177/0091217416636601</pub-id><pub-id pub-id-type="pmid">27079779</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiihonen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.4320</pub-id><pub-id pub-id-type="pmid">30785608</pub-id><pub-id pub-id-type="pmcid">PMC6495354</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenheck</surname><given-names>R</given-names></name><etal/></person-group><article-title>Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol</article-title><source>J Clin. Psychiatry</source><year>2000</year><volume>61</volume><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.4088/JCP.v61n0511</pub-id><pub-id pub-id-type="pmid">10847315</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunebaum</surname><given-names>MF</given-names></name><name name-style="western"><surname>Weiden</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name></person-group><article-title>Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study</article-title><source>J. Clin. Psychiatry</source><year>2001</year><volume>62</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.4088/JCP.v62n0515</pub-id><pub-id pub-id-type="pmid">11411825</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name><etal/></person-group><article-title>Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents</article-title><source>Child Adolesc. Psychiatr. Clin. N. Am.</source><year>2006</year><volume>15</volume><fpage>177</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.chc.2005.08.007</pub-id><pub-id pub-id-type="pmid">16321730</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddad</surname><given-names>PM</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>SG</given-names></name></person-group><article-title>Adverse effects of atypical antipsychotics: differential risk and clinical implications</article-title><source>CNS Drugs</source><year>2007</year><volume>21</volume><fpage>911</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.2165/00023210-200721110-00004</pub-id><pub-id pub-id-type="pmid">17927296</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hynes</surname><given-names>C</given-names></name><etal/></person-group><article-title>Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort</article-title><source>Ther. Adv. Psychopharmaco.l</source><year>2020</year><volume>10</volume><fpage>2045125320957119</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2045125320957119</pub-id><pub-id pub-id-type="pmcid">PMC7522839</pub-id><pub-id pub-id-type="pmid">33029344</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portela</surname><given-names>R</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>ML</given-names></name><name name-style="western"><surname>Castel</surname><given-names>S</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>HN</given-names></name><name name-style="western"><surname>Ruas</surname><given-names>CM</given-names></name></person-group><article-title>Risk factors associated with readmissions of patients with severe mental disorders under treatment with antipsychotics</article-title><source>BMC Psychiatry</source><year>2022</year><volume>22</volume><fpage>189</fpage><pub-id pub-id-type="doi">10.1186/s12888-022-03794-6</pub-id><pub-id pub-id-type="pmid">35300649</pub-id><pub-id pub-id-type="pmcid">PMC8931964</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acosta</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables</article-title><source>Schizophr. Res.</source><year>2009</year><volume>107</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2008.09.007</pub-id><pub-id pub-id-type="pmid">18849150</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gearing</surname><given-names>RE</given-names></name><name name-style="western"><surname>Charach</surname><given-names>A</given-names></name></person-group><article-title>Medication adherence for children and adolescents with first-episode psychosis following hospitalization</article-title><source>Eur. Child Adolesc. Psychiatry</source><year>2009</year><volume>18</volume><fpage>587</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1007/s00787-009-0018-7</pub-id><pub-id pub-id-type="pmid">19381709</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nonadherence to medication four years after a first episode of psychosis and associated risk factors</article-title><source>Psychiatr. Serv.</source><year>2010</year><volume>61</volume><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1176/ps.2010.61.2.189</pub-id><pub-id pub-id-type="pmid">20123826</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis</article-title><source>J. Clin. Psychopharmacol.</source><year>2010</year><volume>30</volume><fpage>565</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e3181f058a0</pub-id><pub-id pub-id-type="pmid">20814327</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>V</given-names></name><etal/></person-group><article-title>Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2012</year><volume>68</volume><fpage>1647</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1007/s00228-012-1298-2</pub-id><pub-id pub-id-type="pmid">22573134</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>CLM</given-names></name><etal/></person-group><article-title>Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis</article-title><source>Schizophr. Res.</source><year>2016</year><volume>174</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2016.03.026</pub-id><pub-id pub-id-type="pmid">27050476</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>JP</given-names></name><name name-style="western"><surname>Icten</surname><given-names>Z</given-names></name><name name-style="western"><surname>Alas</surname><given-names>V</given-names></name><name name-style="western"><surname>Benson</surname><given-names>C</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>K</given-names></name></person-group><article-title>Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations</article-title><source>BMC Psychiatry</source><year>2017</year><volume>17</volume><fpage>346</fpage><pub-id pub-id-type="doi">10.1186/s12888-017-1507-8</pub-id><pub-id pub-id-type="pmid">29047368</pub-id><pub-id pub-id-type="pmcid">PMC5648472</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conus</surname><given-names>P</given-names></name><etal/></person-group><article-title>Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication</article-title><source>Schizophr. Res.</source><year>2017</year><volume>185</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2016.12.029</pub-id><pub-id pub-id-type="pmid">28065484</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daneault</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms</article-title><source>Acta Psychiatr. Scand.</source><year>2019</year><volume>139</volume><fpage>336</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1111/acps.13011</pub-id><pub-id pub-id-type="pmid">30712261</pub-id><pub-id pub-id-type="pmcid">PMC6426680</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>R</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>R</given-names></name></person-group><article-title>Effects of medication nonadherence and comorbidity on health resource utilization in schizophrenia</article-title><source>J. Manag. Care Spec. Pharm.</source><year>2019</year><volume>25</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">30589635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2019.25.1.037</pub-id><pub-id pub-id-type="pmcid">PMC10397586</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezansoff</surname><given-names>SN</given-names></name><name name-style="western"><surname>Moniruzzaman</surname><given-names>A</given-names></name><name name-style="western"><surname>Somers</surname><given-names>JM</given-names></name></person-group><article-title>Temporal associations between medication adherence for patients with schizophrenia and opioid dependence: a 17-year Canadian Cohort Study</article-title><source>Schizophr. Res.</source><year>2019</year><volume>210</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2019.05.031</pub-id><pub-id pub-id-type="pmid">31202570</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Medication adherence in first-episode psychosis patients in Singapore</article-title><source>Early Interv. Psychiatry</source><year>2019</year><volume>13</volume><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1111/eip.12559</pub-id><pub-id pub-id-type="pmid">29521010</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Medication adherence and its correlates among patients affected by schizophrenia with an episodic course: a large-scale multi-center cross-sectional study in China</article-title><source>Asian J. Psychiatr</source><year>2020</year><volume>53</volume><fpage>102198</fpage><pub-id pub-id-type="doi">10.1016/j.ajp.2020.102198</pub-id><pub-id pub-id-type="pmid">32570097</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guitter</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rate and predictors of interrupted patient follow-up after first-episode psychosis&#8212;a retrospective cohort study in France</article-title><source>Early Interv. Psychiatry.</source><year>2020</year><volume>10</volume><fpage>eip.13093</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/eip.13093</pub-id><pub-id pub-id-type="pmid">33350169</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubio</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study</article-title><source>Schizophr. Bull.</source><year>2021</year><volume>47</volume><fpage>1611</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbab063</pub-id><pub-id pub-id-type="pmid">34129663</pub-id><pub-id pub-id-type="pmcid">PMC8530382</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockbridge</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data</article-title><source>BMC Health Serv. Res.</source><year>2021</year><volume>21</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12913-020-06045-0</pub-id><pub-id pub-id-type="pmid">33461561</pub-id><pub-id pub-id-type="pmcid">PMC7812734</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdoux</surname><given-names>H</given-names></name><etal/></person-group><article-title>Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2021</year><volume>271</volume><fpage>1415</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1007/s00406-020-01207-x</pub-id><pub-id pub-id-type="pmid">33169212</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>JH</given-names></name></person-group><article-title>Adherence to antipsychotic drugs by medication possession ratio for schizophrenia and similar psychotic disorders in the Republic of Korea: a retrospective cohort study</article-title><source>Clin. Psychopharmacol. Neurosci.</source><year>2022</year><volume>20</volume><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.9758/cpn.2022.20.3.491</pub-id><pub-id pub-id-type="pmid">35879033</pub-id><pub-id pub-id-type="pmcid">PMC9329107</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirchner</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Medication adherence in a cross-diagnostic sample of patients from the affective-to-psychotic spectrum: results from the PsyCourse study</article-title><source>Front. Psychiatry</source><year>2022</year><volume>12</volume><fpage>713060</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2021.713060</pub-id><pub-id pub-id-type="pmid">35126191</pub-id><pub-id pub-id-type="pmcid">PMC8811370</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>